Improved Postprandial Glycemic Control During Treatment With Humalog Mix25, a Novel Protamine-Based Insulin Lispro Formulation

Objective
Humalog Mix25 is a manufactured premixed insulin formulation containing insulin lispro and a novel insulin lispro-protamine formulation (NPL) in a ratio of 25:75%. The objective of this study was to compare Humalog Mix25 to human insulin 30/70 (30% regular insulin/70% NPH) with respect to glycemic control. 

Research Design and Methods
Humalog Mix25 was compared with human insulin 30/70 in 89 individuals with type 2 diabetes during a 6-month randomized open-label two-period crossover study. Each insulin was administered twice daily, before the morning and evening meals. Information regarding self-monitored blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG <3.0 mmol/L), insulin dose, and HbA1C was collected. 

Results
Treatment with Humalog Mix25 resulted in better postprandial glycemic control after the morning and evening meals compared with treatment with human insulin 30/70. Overall glycemic control and the incidence of hypoglycemia were comparable between the treatments. 

Conclusions
In comparison to treatment with human insulin 30/70, twice daily administration of Humalog Mix25 resulted in improved postprandial glycemic control, similar overall glycemic control, and the convenience of dosing immediately before meals. 



Roach P, Yue L, Arora V. The Humalog Mix25 Study Group. Improved Postprandial Glycemic Control During Treatment With Humalog Mix25, a Novel Protamine-Based Insulin Lispro Formulation. Diabetes Care. 1999;22:1258-1261. 

Last Modified: 2/4/2013